510(k) K202574
K202574 is an FDA 510(k) premarket notification submitted by DiaSorin, Inc. for the device "LIAISON Lyme IgG, LIAISON Lyme IgG Control Set, LIAISON Lyme Total Antibody Plus". The FDA issued a decision of Substantially Equivalent on February 18, 2021. The device falls under product code LSR (Reagent, Borrelia Serological Reagent), a Class II device regulated under 21 CFR 866.3830. DiaSorin, Inc. has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- February 18, 2021
- Date Received
- September 4, 2020
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Reagent, Borrelia Serological Reagent
- Device Class
- Class II
- Regulation Number
- 866.3830
- Review Panel
- MI
- Submission Type